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Rheumatoid Cachexia: causes, 
significance and possible interventions
George S. Metsios1,2, Antonis Stavropoulos-Kalinoglou1,2, 
Yiannis Koutedakis3, George D. Kitas1,4
A B S T R A C T
Rheumatoid arthritis is a chronic autoimmune disease characterised by joint pain and 
stiffness but also systemic mutli-organ involvement. Several features are due to exces-
sive production of inflammatory cytokines, particularly tumour necrosis factor alpha, 
interleukin-1 and interleukin-6. These are implicated in both local synovial inflam-
mation, which causes joint destruction, but also systemic inflammation, which can 
cause loss of body cell mass, amongst other phenomena. Body cell mass breakdown 
in rheumatoid arthritis leads to the classical, but largely ignored, metabolic abnor-
mality known as rheumatoid cachexia. Cachexia is a very strong predictor of adverse 
functional outcome and death in many disease states. In this review we highlight the 
mechanisms linked with rheumatoid cachexia and discuss possible interventions that 
may limit this in patients with rheumatoid arthritis.
I N T R O D U C T I O N
With an estimated prevalence of 0.5–1% in Europe and North America (cur-
rently 0.8% of the adult population in the UK) [1], rheumatoid arthritis (RA) is the 
commonest chronic inflammatory joint disease and affects more women than men. 
The cause of RA remains unknown, but genetic predisposition, aberrant immune 
responses, and physical stress have, amongst others, been identified as significant 
factors in its pathogenesis.
The main site of inflammation in RA is the synovial membrane (synovium). Rheu-
matoid synovium becomes a hyperplastic, highly vascularised tissue heavily infiltrated 
by chronic inflammatory cells. RA is genetically linked to certain major histocom-
patibility complex class II antigens (HLA-DRB1*0404 and 0401). Class II molecules 
present antigenic peptides to CD4+ T cells, and this suggests that RA is caused by a, 
yet unidentified, antigen. CD4+ activated T lymphocytes are central to rheumatoid 
chronic synovitis. They can stimulate monocytes, macrophages and synovial fibroblasts 
to produce cytokines such as interleukins (IL) -1 and 6 and tumour necrosis factor 
alpha (TNFá). Through cell-surface signaling (e.g. CD69 and CD11 or CD40 ligand 
and CD28) or through the release of specific cytokines (e.g. interferon gamma, IL-17 
and others) they also regulate the secretion of matrix metalloproteinases (MMPs) and 
other effector molecules (e.g. free radicals) from macrophages and the stimulation of B 
cells to produce antibodies. Activated inflammatory cells and their products may have 
multiple effects. They can promote further inflammatory cell recruitment by activating 
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endothelial cells to express adhesion molecules and by releas-
ing chemokines such as IL-8: this could, in part, explain the 
flares and overall chronicity of the disease. They can stimulate 
neo-angiogenesis, which would explain the increased vascular-
ity of the inflamed synovium. They may be involved in cartilage 
and bone degradation through multiple mechanisms including 
MMP and free radical release, and direct effects on osteoclasts 
and chondrocytes, which can explain the erosive damage to 
the joint [2]. The main inflammatory cytokines, IL-1, IL-6 and 
TNFá, also have important effects on distant organs, e.g. the 
liver, muscle, fat and vascular endothelium. These systemic 
effects explain several other phenomena, including the acute 
phase response (which is used for monitoring the inflamma-
tory activity of RA in every-day clinical practice), rheumatoid 
cachexia [3] (the loss of lean body mass), and a constellation 
of effects, which may collectively promote atherogenesis [4,5] 
(e.g. dyslipidaemia, insulin resistance, thrombogenesis, and 
endothelial dysfunction amongst others). It is interesting that 
the extent of inflammatory activity in RA, assessed by the 
acute phase response (e.g. erythrocyte sedimentation rate, 
or C-reactive protein), clinical measures (e.g. joint swelling) 
or indices combining both, associates not only with the extent 
of joint damage and disability, but also with cardiovascular 
events and death [6-10]. Effective control of inflammatory 
activity using disease-modifying anti-rheumatic drugs, may, 
in contrast, confer functional and survival benefits [11-15], 
but there may be significant differences between individual 
drugs, requiring further investigation.
The metabolic alterations associated to prolonged over-
production of cytokines in RA are significant. Nearly 2/3 of 
all individuals with RA experience a metabolic abnormality 
accompanied by wasting of muscle mass, with the presence of 
stable or even increased fat mass, and no weight loss [16]. This 
is referred to as rheumatoid cachexia (RC). This condition is 
developed in RA with no clinical evidence of malabsorption or 
impaired liver or renal function [17], and the exact underlying 
mechanisms are not yet entirely clear. Nevertheless, possible 
contributing factors may be the overproduction of TNFá [16], 
the synergy of TNFá with IL-1b, other cytokines, hormones 
and transcription factors active on muscle [18], reduced pe-
ripheral insulin action [19,20], and physical inactivity [3] (Fig. 
1). In this review, we concentrate on the definition of RC and 
the most important mechanisms involved in its pathogenesis, 
i.e. cytokine overdrive and physical inactivity, both of which 
may be subject to successful therapeutic intervention.
R H E U M A T O I D  C A C H E X I A :  D E F I N I T I O N  
A N D  C O N S E Q U E N C E S
Skeletal muscle mass along with visceral and immune sys-
tem mass constitute the body cell mass (BCM). This accounts 
for about 95% of the total metabolic activity of the human 
body [21]. Loss of BCM leads to reduced energy expenditure, 
compromised muscular strength, balance and movement abil-
ity, and impaired immune function [22]. BCM losses greater 
than 40% of baseline values associate with almost certain 
death [23,24].
In general, BCM losses are associated with qualitative 
and quantitative declines in skeletal muscle mass, termed 
sarcopenia, and occur with normal aging. Indeed, signifi-
cant differences have been reported when BCM of normal 
older adults was compared to that of younger individuals 
[25]. Although sarcopenia does not require the presence of 
a disease, this age-related loss of BCM and skeletal muscle 
mass can be significantly enhanced by the presence of chronic 
diseases [26].
RA can occur at any age, but the overwhelming majority 
of prevalent RA cases are predominantly middle-aged and 
elderly individuals, so some age-related sarcopenia would be 
expected. However, RA patients experience an accelerated 
involuntary BCM loss, predominantly in the skeletal muscle 
[16], over and above that normally expected. This condition, 
which is clearly different from sarcopenia, is termed cachexia 
and connotes the loss of BCM occurring due to the illness 
rather than normal aging [27]. The term RC is used specifically 
for patients with RA and dates back to the original description 
of the disease [28]. In RA, BCM loss has been associated with 
muscle weakness and limited mobility, thus reduced functional 
ability and quality of life [29,30]. However, RC in RA is also 
accompanied by little or no weight loss in the presence of 
stable or increased fat mass: this has led to the introduction 
of the term “rheumatoid cachectic obesity” [3] and may be of 
FIGURE 1. Contributing Factors to the Development and Pro-
gression of Rheumatoid Cachexia.
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great importance. It essentially suggests that RA patients with 
normal or near normal body mass index (BMI) may have a 
significantly higher fat component in their body composition 
than age, sex and BMI-matched controls. This increased fat 
mass may be responsible for intensification and perpetuation 
of the inflammatory response, as adipose tissue represents 
one of the predominant sources of IL-6 in the body [31,32]. It 
may also relate to the well-described association of RA with 
increased overall and cardiovascular mortality [4].
R H E U M A T O I D  C A C H E X I A  A N D  E N E R G Y  
E X P E N D I T U R E
Daily energy expenditure (DEE) consists of resting energy 
expenditure (REE) (i.e. the amount of energy required for 
the body to sustain physiological processes at rest), energy 
expended for physical activity and bodily movement in general, 
and the thermic effect of feeding. REE accounts for 70% 
of DEE [33] and in normal individuals is highly depended 
on BCM [34]. In RA patients, however, the relation between 
BCM and REE seems to be altered. Such individuals, exhibit 
significantly decreased BCM with increased REE, accompa-
nied by increased whole-body protein catabolism. These are 
both driven by pro-inflammatory cytokines and their co-exist-
ence leads to RC [3].
S P E C I F I C  M E C H A N I S M S
The exact pathophysiological mechanisms underlying the 
development of RC are not yet fully understood. They include: 
a) excessive cytokine production, b) reduced peripheral insulin 
action, and c) physical inactivity.
C Y T O K I N E S
Cytokines are extracellular peptides influencing cell 
proliferation, migration and behaviour by acting upon them 
through specific receptor interactions. They are produced 
mainly from cells of the immune system such as monocytes/
macrophages and T-cells, but also skeletal muscle, fat and 
other tissues [35,2]. Although their key physiological role is 
homeostasis, activation of inflammatory mechanisms, repair 
and remodelling of damaged tissue, they are also the main 
orchestrators of the dysregulated responses seen in chronic 
inflammatory autoimmune diseases. The pro-inflammatory 
cytokines TNFá, IL-1b, and IL-6 are key to the development 
and perpetuation of the local and systemic inflammatory re-
sponse observed in RA. The predominant stimuli, sources and 
functional effects of IL-1 and TNFá are shown in Figure 2.
TNFá was first identified as ‘cachectin’ after its catabolic 
function. TNFá is involved in biological processes which go 
well beyond its pro-inflammatory functions [36], possibly due 
to the differential bioactivities of its soluble and trans-mem-
brane form [37]. TNFá is intimately involved in the metabolic 
abnormalities observed in RA, leading to significant skeletal 
muscle wasting and augmentation in energy expenditure and, 
thus, the occurrence of RC. Concurrent overproduction of 
TNFá and IL-1â during the acute-phase response in RA 
causes several systemic changes which, in turn, contribute to 
metabolic alterations [38]. They significantly affect muscle 
metabolism by enhancing protein catabolic processes [18]. 
Since the within the muscle balance of protein degradation and 
re-synthesis is not maintained, continuing cytokine overdrive 
will tip the balance towards protein breakdown [3]. This is in 
line with more recent data which revealed that TNFá and IL-
1 contribute to central nervous system side affects, increase 
muscle metabolism and bone marrow suppression, all of which 
are present in chronic inflammatory diseases [39].
The exact biochemical mechanisms by which skeletal mus-
cles undergo rapid protein loss in response to cytokines, have 
been frequently studied in vivo and in vitro given that muscle 
wasting is present in many serious diseases, such as cancer, 
renal failure, HIV and RA. Enhanced muscle proteinolysis 
seems to occur through the ubiquitin-proteasome pathway 
[40], as protein catabolism is targeted by conjugation to ubiq-
uitin [41]. In some inflammatory diseases, TNFá is thought 
to stimulate muscle catabolism via an NF-kappaB-dependent 
process that increases ubiquitin conjugation to muscle pro-
teins [42]. Through a cascade of processes, TNFá bound to 
surface receptors activates the transcriptional NF-kB pathway 
leading to the degradation of a protein I-kBa that inhibits 
NF-kB [43,44]. NF-kB is one of the most important signal 
transduction pathways in RA as it is engaged in mediating the 
production of IL-1 and TNFá and their effects on target cells 
after they have bound to cell surface receptors [39].
TNFá may also cause reduced protein synthesis through 
reduced insulin action, as it interferes with the insulin recep-
tor signalling pathway [45]. Several studies suggest that RA 
associates with reduced peripheral insulin action [19,20]. 
Insulin triggers intracellular enzyme activity that facilitates 
protein synthesis by increased amino acid transport through 
the plasma membrane, RNA cellular levels, and protein for-
mation by ribosomes [46].
FIGURE 2. Effects of IL-1 and TNFα in inflammation.
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administration of TNFá and IL-1 blocking agents, whereas 
anti-IL-6 therapy will soon also become available. In the 
meantime, enhanced physical activity and lifestyle changes 
may be a reasonable route to take in RA patients, as it is 
safe, associates with several other health benefits, and with 
concerted effort can be provided by health care systems and 
achieved by RA patients.
In normal individuals, health status is highly influenced 
by lifestyle and physical activity. Active lifestyle and increased 
levels of physical activity have been associated with decreased 
body fat, increased aerobic capacity, muscular strength and 
overall health [53]; even with increased life expectancy [54] 
while sedentary lifestyle and physical inactivity have the op-
posite results [55].
Patients with RA tend to lead a sedentary lifestyle and 
refrain from physical activity, mainly due to joint pain and 
inflammation, and for fear of aggravating their disease [16]. 
Consequently, they experience many, if not all of the health 
problems related to sedentarity. The presence of chronic in-
flammation further worsens this. Indeed, in patients with RA, 
deficits of up to 40% in aerobic capacity have been reported; 
muscle strength in isometric knee extension is 18–60 % lower 
and flexibility in joints suffering from RA is 20–60 % lower. 
In functional tasks, such as walking a certain distance or 
climbing stairs, studies have reported deficits of up to 60% 
in RA patients. Also increased energy expenditure (30-50 % 
more than healthy peers) ventilation (up to 27%) and heart 
rate (19%) at sub-maximal workloads, often result in earlier 
onset of fatigue, limited endurance and poor neuromuscular 
control. Thus most of the patients stop exercise due to factors 
related to exercise intolerance and not pain or other factors 
related to the disease [56].
Most researchers who studied the effects of exercise 
on RA patients, used intensities of 60-80 % and duration 
of 15-60 min, 3-4 times a week. Results demonstrate 12-21 
% improvements in cardiovascular performance and 0-55% 
increase in strength depending on the type of exercise, as 
well as significant increases in flexibility [57]. Even though 
many participants in these studies were de-conditioned at the 
beginning of the experiments, they were able to exercise at 
levels necessary to produce a training effect. An unexpected 
effect of exercise is the reduced joint swelling experienced by 
some persons after aerobic exercise. Moreover, individuals 
who exercised more than five hours per week experienced less 
progression of joint damage, less hospitalization, less work 
disability and no difference in clinically active joints than 
those who did not exercise [58].
Specifically for the prevention of RC, strength training is 
the most important non-pharmacological treatment. Muscle 
growth and/or maintenance require sufficient physiological 
stimuli. The beneficial effects of strength exercise in the 
maintenance of adequate age-related strength levels have 
been well-established. Strength training programs elicit 
IL-1 and IL-6 have also been proposed as mediators of 
muscle protein degradation in different catabolic conditions. 
However, the proteinolytic mechanisms involved are not yet 
fully understood [47,48].
Human studies demonstrate the association between ex-
cess TNFá and IL-1â with RC, but have failed to directly link 
these pro-inflammatory cytokines with the exact mechanism 
of muscle wasting. By blocking either TNFá with a recom-
binant soluble TNFá receptor or IL-1â with a recombinant 
IL-1 receptor antagonist, it was found that blocking TNFá 
alone only moderately reduced the loss of skeletal muscle 
weight. Blocking both TNFá and IL-1â was more effective 
in preventing undue muscle wasting, indicating that TNFá is 
an important element in this process, but possibly not on its 
own [49]. It remains unclear whether these cytokines promote 
protein degradation or restrain protein synthesis, and whether 
their effects are direct or through a network of many other 
hormones and cytokines.
R E D U C E D  P H Y S I C A L  A C T I V I T Y
RA is a chronic progressive disease of the joints associated 
with systemic involvement, significant morbidity, deformity, 
and diminished quality of life. Structural damage in the 
musculoskeletal system can be developed within the first two 
years of the disease [50]. Pain, joint stiffness and inflamma-
tion, fatigue and reduced muscle strength are all elements of 
RA symptomatology [51]. Physical activity can therefore be 
significantly compromised in RA patients.
In general, reduced physical activity is associated with an 
alteration in normal physiological processes leading to muscle 
atrophy, loss of ability for exercise, insulin resistance, and 
energy balance variations. Bed-rest studies reveal that lack of 
effective muscle stimuli decreases the turnover rates of muscle 
and whole-body proteins, with a prevailing inhibition of pro-
tein synthesis [52]. These factors might also be contributing 
to the initiation and/or progression of RC.
P O S S I B L E  I N T E R V E N T I O N S
Since the exact causes of RC are not fully delineated, no 
definite preventive or therapeutic strategies have been tested 
to-date. The introduction of anti-TNFá therapy may provide 
an opportunity to address this problem, but this requires 
prospective assessment. It is a common clinical observation 
that RA patients receiving anti-TNF therapy commonly and 
rapidly put on weight. It remains unclear whether this is due 
to a significant change to their body composition and reversal 
of RC, i.e. whether it is predominantly due to muscle gain or 
fat gain. Ongoing research in our laboratory investigates the 
effects of anti-TNFá administration on body composition 
(body fat and muscle mass) and REE and we will hopefully 
be able to clarify this. Future directions may involve the co-
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significant improvements in muscle strength levels in healthy 
adults [59] even in healthy elderly adults [60]. In RA, long-
term high-intensity exercise programs are more effective 
than physiotherapy care in improving functional ability of 
RA patients [61]. Also, significant improvements in muscu-
lar strength may be attained with either a low-volume or a 
high-volume program [62]. Along with effectiveness, these 
programs are safe since, in well-controlled and recent-onset 
individuals with RA, application of high-intensity exercise 
regimes has been found to elicit significant improvements in 
neuromuscular performance, without aggravating joint pain 
or damage [63,64].
Apart from strength training, adopting a more active 
lifestyle can result in health benefits in conditions such as 
diabetes [65] and metabolic syndrome [66], and probably in 
RA. Most importantly, physically active individuals can main-
tain a higher level of physical functioning, reduce the rate of 
age-related muscle wasting [67], and improve life-satisfaction 
and well-being [68]. The effects of lifestyle changes in RA 
have not been investigated.
C O N C L U S I O N S
The exact mechanisms involved in the pathogenesis of 
RC remain unclear. In a synergistic manner TNFá and IL-1 
significantly enhance muscle catabolic processes but it remains 
unknown whether this is due to enhanced protein degradation 
or reduced protein re-synthesis. Reduced peripheral insulin 
activity and physical inactivity may also play a significant 
role in the maintenance and/or progression of this condition. 
Due to the fact that RC increases comorbidity and may be 
contributing to mortality, future research must focus on the 
understanding and prevention of this complication. Current 
preventive methods could include exercise programs and 
physically active lifestyles. The potentially beneficial effects 
of biological therapies need to be fully evaluated.
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